• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aerocrine completes $50M debt and equity financing

Aerocrine completes $50M debt and equity financing

May 1, 2013
CenterWatch Staff

Aerocrine, a medical products company, has completed a financing with an affiliate of the U.S. investment firm OrbiMed Advisors and with Novo consisting of $35 million of debt. Aerocrine also raised $ 15 million of equity from OrbiMed and a number of institutional investors through a directed share issue.

Aerocrine will utilize the proceeds to continue funding growth and expanded commercialization of its current product, as well as its pipeline of new devices for diagnosis and management of airway inflammation. Based on its long term plan, the company believes that this funding will be sufficient to reach positive cash flow and profitability.

"Aerocrine has worked closely with OrbiMed over the last several months to craft a financing structure that funds the company through its next stages of growth and towards profitability,” said Scott Myers, CEO of Aerocrine.

Matthew Rizzo, managing director of OrbiMed, added, “Aerocrine has made substantial progress with the commercialization of Niox Mino and we look forward to working with Scott and his team to help the company achieve its full potential.”

Aerocrine has been focusing its commercialization efforts in the U.S. and other key international markets. These efforts require sustained funding to support this expansion. The combination of debt and equity should provide a proper capital structure for a growth company like Aerocrine.

ABG Sundal Collier acted as sole lead manager and bookrunner in the equity financing. Mannheimer Swartling and Reed Smith acted as Aerocrine's legal advisers in the financing.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing